Buy Opportunity for NVO

Novo Nordisk A/S – Financial Summary and Outlook (2024):

Sales Growth: Up 23% in Danish kroner (DKK 204.7 billion) and 24% at constant exchange rates (CER).
Operating Profit: Increased by 21% (DKK 91.6 billion).
Net Profit: Rose 18% to DKK 72.8 billion.
Product Highlights:

Wegovy (Obesity): Sales surged 48% in Q3 (DKK 17.3 billion).
Ozempic (Diabetes): Slight sales dip but remains a key contributor.
Challenges:

CagriSema Trial: Missed expected weight-loss targets, leading to stock decline.
Outlook:

Adjusted sales growth forecast: 23%-27%; operating profit: 21%-27% (CER).
Focus remains on high-demand products (Wegovy, Ozempic) and R&D for future growth.